Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CBP/p300 bromodomain inhibitor
SGC-CBP30 is a potent and selective inhibitor of CREBBP (CBP) and EP300; which are general transcriptional co-activators.- Kevin Bohm, .et al. , Arch Pharm (Weinheim), 2023, Jul;356(7):e2200661 PMID: 37196427
-
KAT5 (Tip60) HAT inhibitor
MG149 is a potent histone acetyltransferase inhibitor with IC50 of 74 uM and 47 uM for Tip60 and MOF.- Thibaud Reyser, .et al. , Pharmaceutics, 2023, Oct 10;15(10):2440 PMID: 37896200
-
p300/CBP inhibitor
C646 is a selective p300/CREB-binding protein (CBP) inhibitor (Ki = 400 nM).- Thibaud Reyser, .et al. , Pharmaceutics, 2023, Oct 10;15(10):2440 PMID: 37896200
- Zhifeng Zhang, .et al. , PLoS One, 2017, 12(10): e0186900 PMID: 29049411
-
p300/CBP bromodomain inhibitor
Inobrodib (CCS-1477) is a potent p300/CBP bromodomain inhibitor.
-
p300/CBP histone acetyltransferase inhibitor
P300/CBP-IN-3, a p300/CBP histone acetyltransferase inhibitor. -
KAT5 (Tip60) HAT inhibitor
NU9056 is an selective KAT5 (Tip60) HAT inhibitor. IC50 values are < 2, 60, 36, and >100 μM for KAT5, p300, pCAF and GCN5, respectively. Inhibits protein acetylation in prostate cancer cell lines and blocks DNA damage response. Decreases proliferation of LNCaP cells; induces apoptosis via caspase activation. -
NAT10 inhibitor
Remodelin Hydrobromide is a potent acetyl-transferase NAT10 inhibitor. -
KAT5 (Tip60), p300/PCAF inhibitor
Anacardic Acid is a potent inhibitor of p300 and p300/CBP-associated factor histone acetyltranferases. -
Tip60 HAT Inhibitor
TH1834 dihydrochloride is a selective inhibitor of Tip60 (KAT5), a histone acetyltransferase involved in the regulation of gene expression and DNA repair. This compound has been shown to induce apoptosis and enhance DNA damage in breast cancer cells, demonstrating its potential as a therapeutic agent in cancer research. Importantly, TH1834 dihydrochloride does not inhibit the activity of the structurally related histone acetyltransferase MOF, suggesting a targeted approach in modulating histone acetylation and cellular responses. -
Tip60 HAT Inhibitor
TH1834 is a selective inhibitor of the Tip60 (KAT5) histone acetyltransferase (HAT). This compound has demonstrated the ability to induce apoptosis and enhance DNA damage in breast cancer cells. Notably, TH1834 does not interfere with the activity of the related MOF HAT, making it a valuable tool for investigating the role of Tip60 in cancer biology and exploring potential therapeutic applications. -
p300 inhibitor
Histone Acetyltransferase Inhibitor II is a potent and cell permeable p300 inhibitor, with an IC50 of 5μM; Histone Acetyltransferase Inhibitor II can be used in cancer research. -
histone acetyltransferase Gcn5 inhibitor
Butyrolactone 3 (MB-3) is a specific small-molecule inhibitor of the histone acetyltransferase Gcn5, exhibiting an IC₅₀ of 100 μM and binding affinity comparable to that of its natural substrate, histone H3. It displays weak inhibitory activity against CBP (IC₅₀ = 0.5 mM), indicating high selectivity for Gcn5. By modulating histone acetylation and epigenetic regulation, Butyrolactone 3 serves as a valuable research tool for exploring the roles of Gcn5 in cancer, metabolic disorders, autoimmune diseases, and neurological conditions. -
p300/CBP inhibitor
NEO2734 (EP31670) is an orally active dual inhibitor of p300/CBP and BET bromodomains, with IC₅₀ values of <30 nM for both targets. It is effective in both SPOP-mutant and wild-type prostate cancer models. -
CBP/p300 inhibitor
CBP/p300-IN-8 is a potent inhibitor of the CBP/p300 family of bromodomains, with an IC₅₀ of 0.01–0.1 µM for CBP. It also inhibits BRD4 activity with significantly lower potency (IC₅₀ = 1–1000 µM). -
p300/CBP inhibitor
CBP/p300-IN-12 is a potent and selective covalent inhibitor of the histone acetyltransferases p300 and CBP, with an IC₅₀ of 166 nM for p300. It reduces H3K27Ac levels in PC-3 cells with an EC₅₀ of 37 nM and forms a covalent adduct with cysteine residue C1450. -
KIX-KID interaction inhibitor
Naphthol AS-E is a potent, cell-permeable inhibitor of the KIX-KID interaction. It binds directly to the KIX domain of CBP with a Kd of 8.6 μM and inhibits the interaction between the KIX domain and the KID domain of CREB with an IC₅₀ of 2.26 μM. Naphthol AS-E is applicable in cancer research. -
EP300/CBP HAT Inhibitor
CBP/p300-IN-17 is a potent inhibitor of the EP300 and CBP histone acetyltransferases (HATs), exhibiting IC50 values of 0.18 µM and 0.69 µM for EP300 and LK2 H3K27, respectively. This compound demonstrates significant biological activity in modifying histone acetylation, making it valuable for research in epigenetics, cancer biology, and transcriptional regulation. Its selective inhibition of EP300 and CBP provides a critical tool for investigating their roles in various cellular processes and disease states. -
P300 HAT Inhibitor
P300-IN-6 is an orally bioavailable inhibitor targeting the histone acetyltransferase p300 HAT domain, exhibiting a human IC50 of 7 nM. This compound effectively suppresses c-Myc expression and reduces acetylation levels of histones H3K18 and H3K27, leading to inhibition of cancer cell proliferation. P300-IN-6 demonstrates significant antitumor activity in xenograft mouse models, making it a valuable tool for investigating therapeutic strategies in multiple myeloma research. -
HAT Inhibitor
SYY-B085-1 is a histone acetyltransferase (HAT) inhibitor with specific activity against various HAT enzymes. This compound plays a critical role in the regulation of gene expression and cellular processes by modulating acetylation levels on histones. SYY-B085-1 is utilized in research to explore the effects of HAT inhibition in cancer biology and epigenetic regulation. Its unique mechanism offers valuable insights for studies focused on transcriptional modulation and potential therapeutic interventions. -
p300/CBP HAT Inhibitor
CBP/p300-IN-19 is a potent inhibitor of the histone acetyltransferase (HAT) activity of p300 and CBP, exhibiting IC50 values of 1.4 µM and 2.2 µM, respectively, while showing limited inhibition of PCAF and Myst3 (>100 µM). This compound demonstrates significant anti-tumor activity, making it valuable for research into cancer biology and epigenetic regulation. Its ability to selectively target p300/CBP HAT provides a useful tool for investigating the role of acetylation in various cellular processes and disease states. -
HAT Inhibitor
DS-9300 is a selective inhibitor of the EP300/CBP histone acetyltransferases (HATs) with a potent IC50 value of 28 nM. This compound demonstrates significant anticancer activity and is applicable in prostate cancer research, providing valuable insights into the mechanisms of acetylation in tumorigenesis. DS-9300 serves as a critical tool for studying the role of HATs in cancer progression and therapeutic resistance. -
HAT Inhibitor
NSC 694623 is a potent inhibitor of histone acetyltransferases (HATs), with an IC50 value of 15.9 μM for recombinant p300/CBP-associated factor (PCAF). This compound exhibits antiproliferative effects on various cancer cell lines, making it a valuable tool for cancer research. Its capacity to modulate histone acetylation offers potential insights into epigenetic regulation and therapeutic strategies in oncology. -
p300/CBP HAT Inhibitor
CBP/p300-IN-19 hydrochloride is a selective inhibitor of the histone acetyltransferases (HAT) p300 and CBP, exhibiting IC50 values of 1.4 µM and 2.2 µM, respectively. It demonstrates significant antitumor activity, making it a valuable tool for cancer research. This compound can be applied in studies investigating the roles of acetylation in gene regulation and cell proliferation, as well as in the development of targeted therapies. -
CBP HAT Inhibitor
NiCur is a potent and selective inhibitor of CBP histone acetyltransferase (HAT) with an IC50 value of 0.35 μM. By targeting CBP HAT activity, NiCur effectively downregulates p53 activation in response to genotoxic stress. This compound is suitable for mechanistic studies, allowing researchers to investigate pathways involving histone acetylation without altering the expression of target proteins. -
HAT Inhibitor
SYY-B029-2 is a potent inhibitor of histone acetyltransferases (HATs), exhibiting an IC50 of 1.4 nM. This compound demonstrates significant anti-proliferative effects on human mantle cell lymphoma (MCL) cell line MAVER-1 and human castration-resistant prostate cancer cell line LNCaP clone FGC, with IC50 values of 15 nM and 13 nM, respectively. SYY-B029-2 serves as a valuable tool for research into epigenetic regulation and cancer therapy. -
p300/CBP HAT Inhibitor
B026 is a selective and potent inhibitor of the p300/CBP histone acetyltransferase (HAT) with IC50 values of 1.8 nM for p300 and 9.5 nM for CBP. This compound exhibits significant anticancer activity against androgen receptor-positive (AR+) prostate cancer cell lines, making it a valuable tool for research in cancer biology and epigenetic regulation. Its oral bioavailability enables easy administration for in vivo studies targeting p300/CBP-mediated pathways. -
EP300/CBP HAT Inhibitor
CBP/p300-IN-18 is a potent inhibitor of the EP300 and CBP histone acetyltransferases (HATs), exhibiting IC50 values of 0.056 µM and 0.46 µM for EP300 and LK2 H3K27, respectively. This compound serves as a valuable tool for investigating the role of histone acetylation in various biological processes and disease states. It is particularly useful in studies focused on chromatin remodeling, gene expression, and potential therapeutic applications in cancer and other disorders associated with dysregulated acetylation. -
CBP/p300 Inhibitor
CBP/p300-IN-21 is a selective inhibitor of the CBP/p300 transcriptional co-activators, exhibiting IC50 values of 0.07 μM for p300 and 1.755 μM for CBP. This compound effectively reduces the acetylation level of histone H3 at lysine 18 (H3K18Ac), implicating a potential role in modulating gene expression. Furthermore, CBP/p300-IN-21 has demonstrated efficacy in inhibiting the growth of 4T1 tumors in murine models, highlighting its relevance in cancer research and therapeutic applications. -
CBP/p300 Inhibitor
CBP/p300-IN-15 is a potent inhibitor of the CBP/p300 coactivators, exhibiting IC50 values of 2.50 nM for p300 and 28.0 nM for CBP. This compound demonstrates significant biological activity in ovarian cancer cell lines, with EC50 values of 0.865 μM for OVCAR-3 and 2.71 μM for A2780. CBP/p300-IN-15 is a valuable tool for investigating the role of CBP/p300 in ovarian cancer research and could provide insights into therapeutic strategies targeting these coactivators. -
Ep300/CREBBP Inhibitor
Ep300/CREBBP-IN-3 is a potent inhibitor of the Ep300 and CREBBP enzymes, demonstrating IC50 values of 0.056 μM and 0.095 μM, respectively. This compound is primarily utilized in cancer research, facilitating investigations into the role of histone acetylation in tumor progression and therapy resistance. Its ability to selectively inhibit these acetyltransferases makes it a valuable tool for understanding the epigenetic regulation of gene expression in oncology. -
HAT Inhibitor
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor that specifically targets Gcn5, p300/CBP-associated factor (PCAF), CREB-binding protein (CBP), and p300. This compound demonstrates inhibitory activity with IC50 values of 8.39 μM, 9.74 μM, 2.49 μM, and 5.35 μM for each respective HAT. PU139 is valuable for research applications exploring histone acetylation and its roles in gene regulation, cellular signaling, and cancer biology. -
Selective Hhat Inhibitor
RU-SKI 43 hydrochloride is a selective inhibitor of Hedgehog acyltransferase (Hhat) with an IC50 of 850 nM. This compound effectively reduces Gli-1 activation via Smoothened-independent, non-canonical signaling pathways and inhibits Akt and mTOR pathway activity. RU-SKI 43 hydrochloride demonstrates promising anti-cancer effects, making it a valuable tool for research in cancer biology and targeted therapy.
